Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
American College of Obstetricians and Gynecologists | ACOG |
Amniotic fluid index | AFI |
Antiphospholipid antibody syndrome | APLAS |
Assisted reproductive technology | ART |
Biophysical profile | BPP |
Body mass index | BMI |
Central nervous system | CNS |
Contraction stress test | CST |
Deepest vertical pocket | DVP |
Fetal breathing movement | FBM |
Fetal movement counting | FMC |
Human chorionic gonadotropin | hCG |
Intrauterine growth restriction | IUGR |
Lecithin/sphingomyelin ratio | L/S ratio |
Modified biophysical profile | mBPP |
Multiples of the median | MoM |
National Center for Health Statistics | NCHS |
National Institute for Child Health and Human Development | NICHD |
Nonstress test | NST |
Perinatal mortality rate | PMR |
Phosphatidylglycerol | PG |
Pregnancy-associated plasma protein A | PAPP-A |
Rapid eye movement | REM |
Respiratory distress syndrome | RDS |
Systemic lupus erythematosus | SLE |
Vibroacoustic stimulation | VAS |
World Health Organization | WHO |
Antepartum fetal evaluation is a complex balancing act. The goal of evidence-based antepartum fetal evaluation is to decrease perinatal mortality and permanent neurologic injury through judicious use of reliable and valid methods of fetal assessment without acting prematurely to modify an otherwise healthy pregnancy or providing a false sense of well-being in cases of impending morbidity . The opportunity for obstetric care providers to participate in this delicate balance has been made possible by continued advances in our ability to assess the physiologic well-being of the fetus, concurrent with great improvement in neonatal care and survival. However, despite these advances in antepartum fetal surveillance and the widespread use of antepartum testing programs, the ability of these techniques to prevent intrauterine injury or death remains unproved in many cases. The focus of this chapter is on antepartum evaluation in the United States and similarly technologically advanced and resource-rich countries, noting that the worldwide problem of stillbirth is a vast and compelling area of international interest.
Identification of fetuses at risk for perinatal mortality has historically been the goal of antepartum fetal assessment. The implementation of this goal is made more complex by the understanding that (a) long-term neurologic disability is an integrally related and often competing entity to perinatal mortality, and (b) identification of fetal death risk may result in iatrogenic prematurity which itself is a risk for perinatal mortality.
The National Center for Health Statistics (NCHS) provides two different definitions for perinatal mortality, acknowledging that variation in definitions and reporting rates both among states in the United States and throughout different countries worldwide makes comparisons difficult; an agenda to develop a classification consensus has been the focus of a number of international committees, including the National Institute for Child Health and Human Development (NICHD). The NCHS National Vital Statistics Report on fetal and perinatal mortality describes two different definitions for perinatal mortality rate (PMR). Definition I includes deaths of infants of less than 7 days of age and fetal deaths of 28 weeks of gestation or more per 1000 live births plus fetal deaths, whereas definition II is more comprehensive and includes infant deaths of less than 28 days of age and fetal deaths of 20 weeks or more per the same denominator. The definitions of PMR provided by the World Health Organization (WHO) and the American College of Obstetricians and Gynecologists (ACOG) differ slightly and include the number of fetuses and live births weighing at least 500 g rather than using a gestational age cutoff. The term fetal death is used in these definitions and hereafter in this chapter rather than stillbirth, spontaneous abortion, or miscarriage .
Although the PMR has fallen steadily in the United States since 1965, the number of fetal deaths has not changed substantially in the past decade ( Fig. 27.1 ). Using NCHS definition I, the PMR reported in 2013 (most recent data available) was 6.2 per 1000, and fetal deaths accounted for about 50% of all perinatal mortality in the United States. The PMR varies greatly by maternal race and ethnicity ( Fig. 27.2 ). In 2013, rates (per 1000) were 5.25 for non-Hispanic white, 5.58 for Hispanic, and 10.8 for non-Hispanic black women. Although the PMR declined most for non-Hispanic black women between 2006 and 2011, from 11.76 to 10.8, this group continues to experience double the PMR of non-Hispanic white women. The significantly greater PMR in blacks results from higher rates of both neonatal and fetal deaths.
Another way to consider the effect of fetal events on PMR is to look at the infant mortality rate ( Fig. 27.3 ). Although the infant mortality rate includes all deaths of infants younger than 1 year of age, 50% of all infant deaths occur in the first week of life, and 50% of these losses result during the first day of life. In 2017, the leading causes of infant mortality were congenital malformations (21%), disorders related to short gestation and low birthweight (17%), maternal complications (6%), sudden infant death syndrome (6%), and unintentional injuries (6%). Clearly, antepartum and perinatal events play an important role in infant mortality.
In addition to declining frequency in PMR over time, the overall pattern of perinatal deaths in the United States has changed considerably during the past 50+ years. Investigators in the 1980s–90s who studied longitudinal cohorts from the mid- to late 20th century suggested that etiologies for antepartum fetal deaths could be categorized as chronic asphyxia/placental insufficiency, congenital malformations, superimposed complications of pregnancy (such as Rh isoimmunization, placental abruption, and fetal infection—many as a consequence of preterm premature rupture of membranes), and unexplained cause. Decline in the fetal death rates in these cohorts over time was attributed to the prevention of Rh sensitization, antepartum and intrapartum fetal surveillance, improved detection of intrauterine growth restriction (IUGR) and fetal anomalies with ultrasound, and improved care of maternal diabetes mellitus and preeclampsia. The role of antenatal diagnosis and management of congenital malformations and aneuploidy is obviously critical to a goal of reducing perinatal morbidity and mortality and will be discussed separately (see Chapters 9 and 10 ).
With regard to undiagnosed IUGR in particular, this has been identified by many investigators as a potentially preventable contributor to fetal death rates, especially in the gestational period between 28 and 36 weeks (Fretts ). Despite a marked fall in unexplained fetal deaths in the cohorts studied during the second half of the last century, this category was used for more than 25% of all stillbirths and is still the categorization used to describe 30% of fetal deaths in the most recent US National Vital Statistic Report on the subject. Numerous more recent population-based analyses of the causes of fetal death in the United States and other similarly developed nations have been performed, including serial evaluations by the Stillbirth Collaborative Research Network, which utilized rigorous methods to classify as many “unexplained” fetal deaths as possible. This group and others concluded unspecified causes and conditions of placenta/cord/membranes are the leading classifications for fetal death utilized in a modern high-resource population at 25% to 30% each, followed by maternal complications of pregnancy and congenital anomalies at 10% to 15% each ( Fig. 27.4 ; in addition, fetal deaths late in gestation are more likely than earlier gestation fetal deaths to have no identifiable etiology . Regarding our ability to whittle away at the number of unexplained fetal deaths, and thus possibly increase the proportion of deaths that are potentially preventable, many leaders in the field have put out a call to action for standardized and rigorous methodology in clinical and research settings when classifying and cataloguing each fetal death that occurs in high-resource settings.
The ability of our current methods of surveillance to make an impact on perinatal mortality will depend on the ability of available tests to predict and predate injury and on use of obstetric interventions to prevent adverse outcomes. Since the decline in fetal deaths attributable to factors largely considered identifiable and modifiable during routine modern prenatal care, including congenital malformations and Rh isoimmunization, the concept of further progress toward identifying and reducing other causes of potentially preventable fetal deaths has emerged as an important goal. In one British series, obstetric and pediatric assessors reviewed the circumstances surrounding each case of perinatal death to identify any “avoidable” factors that may have contributed to the death. Of the 309 perinatal deaths in this population (half fetal and half in the first week of life), 59% were considered to have had avoidable factors, including 74% of normal-birthweight infants with no fetal abnormalities and no maternal complications. Most avoidable factors were found to be obstetric rather than pediatric, maternal, or social. The failure to respond appropriately to abnormalities during pregnancy and labor—including results from the monitoring of fetal growth or intrapartum fetal well-being, significant maternal weight loss, or reported reductions in fetal movement—constituted the largest groups of avoidable factors. This characterization of avoidable factors that contribute to perinatal death has been confirmed in additional studies. Most recently a study by the US Stillbirth Collaborative Research Network, including a comprehensive analysis of 512 fetal deaths, characterized 22% as potentially preventable. This “potentially preventable” classification was made on the basis of features that could theoretically be detected in an otherwise-viable (>24 weeks and 500 g, no lethal anomalies) fetus based on maternal and fetal risk factors and testing. Of those fetal deaths categorized as potentially preventable, the majority shared a common feature of impaired placental function—a condition theoretically amenable to detection via fetal growth surveillance and perhaps antepartum fetal testing.
Another way to classify fetal deaths may be to differentiate those that occur during the antepartum period and those that occur during labor, or intrapartum deaths. Antepartum fetal death is much more common than intrapartum fetal death, and unexplained fetal death occurs far more commonly than unexplained infant death. In a population-based study in the United States in 2007, the antepartum fetal death rate was 3.7 per 1000, compared with 0.6 per 1000 intrapartum fetal deaths. Although most fetal deaths occur before 32 weeks’ gestation, in planning a strategy for antepartum fetal monitoring, the risk for fetal death must be examined in the population of women who are still pregnant at that point in pregnancy. The understanding that all pregnancies at a given gestational age and at each subsequent point until delivery are at risk for fetal death has led to the development of a metric with which to examine fetal death rates per gestational age, the prospective fetal mortality rate . Rather than compute the fetal mortality rate as number of fetal deaths per 1000 live births or fetal deaths at a given gestational age, the prospective fetal mortality rate is defined as the number of fetal deaths per 1000 live births or fetal deaths at a given gestational age or greater ( Fig. 27.5 ) . When this approach is taken, the data would suggest that fetuses at 40 to 41 weeks are at a threefold greater risk and those at 42 or more weeks are at a 12-fold greater risk for intrauterine death than fetuses at 28 to 31 weeks. The risks are even higher in multiple gestations as pregnancy progresses. For twin gestations, the optimal time for delivery to prevent late-gestation perinatal deaths is before 39 weeks, and for triplets, 36 weeks. The issue of timing is also illustrated by a recent cohort study of over 75,000 singleton pregnancies with fetal growth restriction, the focus of which was to find the point at which the competing risks of fetal death and neonatal death were in balance, in order to inform delivery decisions. In this cohort, the balance point was 32 to 34 weeks.
Some risk factors have a clear etiologic relationship to fetal compromise and death, such as exposures to teratogens or maternal conditions that alter the fetal environment or blood supply or content. Other risk factors—such as epidemiologic factors that include maternal age, race, and body habitus—have a perhaps more complex and less well-understood link to fetal death risk ( Fig. 27.6 ). Common risk factors for fetal death in the United States are listed in Table 27.1 . Many of these conditions can coexist in individual patients, which makes assessment of the contribution of each factor to perinatal mortality a challenge. A recent concept of looking at individual risk factors as part of a “triple risk model” may prove useful in making sense of this challenge, similar to that used to understand contributors to sudden infant death syndrome (SIDS). In this model, proposed by Warland and Mitchell, an interplay exists among maternal, fetal, and placental factors and a stressor. They posit that whereas these factors in isolation may be insufficient to cause fetal death, they may prove lethal in combination ( Fig. 27.7 ). Also necessary to consider is the contribution of these conditions to fetal injury that results in liveborn children with permanent neurologic compromise; this has yet to be determined but is an important alternative outcome to perinatal mortality that deserves further study.
Risk Factor | Prevalence (%) | Odds Ratio |
---|---|---|
All pregnancies | — | 1.0 |
Low-risk pregnancies | 80 | 0.86 |
Obesity: | ||
BMI 25–29.9 | 21–24 | 1.4–2.7 |
BMI >30 | 20–34 | 2.1–2.8 |
Nulliparity compared with second pregnancy | 40 | 1.2–1.6 |
Fourth child or greater compared with second | 11 | 2.2–2.3 |
Maternal age (reference: <35 years): | ||
35–39 years | 15–18 | 1.8–2.2 |
≥40 years | 2 | 1.8–3.3 |
Multiple gestation: | ||
Twins | 2.7 | 1.0–2.2 |
Triplets or greater | 0.14 | 2.8–3.7 |
Oligohydramnios | 2 | 4.5 |
Assisted reproductive technologies (all) | 1–3 | 1.2–3.0 |
Abnormal serum markers: | ||
First-trimester PAPP-A <5% | 5 | 2.2–4.0 |
Two or more second-trimester markers | 0.1–2 | 4.2–9.2 |
Intrahepatic cholestasis | <0.1 | 1.8–4.4 |
Renal disease | <1 | 2.2–30 |
Systemic lupus erythematosus | <1 | 6–20 |
Smoking | 10–20 | 1.7–3.0 |
Alcohol use (any) | 6–10 | 1.2–1.7 |
Illicit drug use | 2–4 | 1.2–3.0 |
Low education and socioeconomic status | 30 | 2.0–7.0 |
Fewer than four antenatal visits a | 6 | 2.7 |
Black (reference: white) | 15 | 2.0–2.2 |
Hypertension | 6–10 | 1.5–4.4 |
Diabetes | 2–5 | 1.5–7.0 |
Large for gestational age (>97% without diabetes) | 12 | 2.4 |
Fetal growth restriction (%): | ||
<3 | 3.0 | 4.8 |
3–10 | 7.5 | 2.8 |
Previous growth-restricted infant | 6.7 | 2.0–4.6 |
Previous preterm birth with growth restriction | 2 | 4.0–8.0 |
Decreased fetal movement | 4–8 | 4.0–12.0 |
Previous stillbirth | 0.5 | 2.0–10.0 |
Previous cesarean section | 22–25 | 1.0–1.5 |
Postterm pregnancy compared with 38–40 weeks | 2.0–3.0 | |
41 weeks | 9 | 1.5 |
42 weeks | 5 | 2.0–3.0 |
Multiple investigators have found that after controlling for comorbidities, women 35 years of age or older have a greater risk for fetal death than women younger than 30 years, and women 40 years or older have an even further increased risk. A relationship exists between maternal age and fetal deaths, with the highest rates in teenagers and women older than 35 years . The interplay of fetal death, maternal age, and gestational age was demonstrated in a population-based 2006 study in the United States of almost 5.5 million births. In this cohort, compared with their counterparts aged 30 to 34 years at 41 weeks of gestation, women older than 35 to 39 years had the same risk for fetal death at 40 weeks, and women older than 40 years had the same risk at 39 weeks. Only 10% of the women older than 35 years had medical comorbidities, and the results of this study did not change when those women were excluded; this highlights the point that the increase in fetal death risk exists in otherwise healthy older gravidas compared with younger women.
The variation in fetal death risk in the United States by maternal race is complex, which makes ascertainment of biologic risk factors related to race difficult. Factors that contribute to increased rates of fetal death among black women compared with white women include disparities in socioeconomic status, access to health care, and preexisting medical conditions. A 2009 population-based study of more than 5 million US births demonstrated that the greatest black-and-white disparity is in preterm perinatal death, with a hazard ratio at 20 to 23 weeks of 2.75, which decreases to 1.57 at 39 to 40 weeks. Associations with fetal death in black women include lower education levels and higher rates of medical, pregnancy, and labor complications, with congenital anomalies more contributory in white women. The study of racial and ethnic disparities in fetal death rates worldwide, and how these intersect with sociodemographic features and what remediating steps could be taken, has been identified as a critically overdue initiative ( Fig. 27.8 ).
Poor access to prenatal care and poor underlying health and nutrition have been linked to increased risk for fetal death both in developing and developed nations. As with other sociodemographic risk factors, these potential influences on fetal death risk are difficult to quantify and may be additive to other high-risk conditions. Smoking and abuse of alcohol or illicit drugs represent potentially modifiable risk factors for fetal death. Although these behaviors are attractive candidates for fetal death prevention through counseling and modification of intake, prospective trials of behavior modification strategies have generally been underpowered for detection of a difference in fetal death with these interventions.
Prepregnancy obesity is associated with increased perinatal mortality, especially in late gestation. This has been demonstrated in several large series, including a meta-analysis of 38 studies that included more than 3 million women. The connection between obesity and increased risk of fetal death is poorly understood, and is made more complex by the frequent comorbidities encountered in patients with prepregnancy obesity. Theoretic contributors to adverse perinatal outcomes in this group include placental dysfunction, sleep apnea, metabolic abnormalities, immune dysregulation and technical challenges in clinical and ultrasound assessment of fetal growth. The strength of the association increases with advancing body mass index (BMI) and with advancing gestational age.
Although historically, insulin-dependent diabetes has been a major risk factor for fetal death, the fetal death rate in women with optimal glycemic control now approaches that of women without diabetes. However, the relationship between glycemic control and fetal death remains uncertain. Poor glycemic control is associated with increased perinatal mortality, in large part as a result of congenital anomalies; indicated preterm deliveries; and sudden, unexplained fetal death. A 2014 population-based study of over 1 million births in Ontario, Canada, revealed an odds ratio of 2.3 for fetal death among women with pregestational diabetes compared with those without diabetes. No evidence suggests that gestational diabetes controlled by diet alone is associated with increased rates of intrauterine fetal death, while data are mixed regarding any increase in the odds of fetal death attributable to gestational diabetes requiring treatment with hypoglycemic agents.
Studies have shown conflicting evidence regarding whether fetal death rates with well-controlled preexisting hypertension are comparable to those in the general population or increased. The increased risk for perinatal mortality associated with hypertension is most often related to complicated hypertension, with sequelae of placental insufficiency that include IUGR and oligohydramnios. Pregnancy-induced hypertension, especially preeclampsia with severe features or eclampsia, may be associated with fetal death through placental and coagulation-related pathways, including placental abruption.
In general, no demonstrable link has been found between inherited thrombophilia and risk for fetal death. Although initial reports seemed to support an association between fetal death and thrombophilia, such as factor V Leiden mutation and prothrombin gene mutation, large prospective trials have failed to substantiate this association. The presence of circulating maternal antiphospholipid antibodies—in particular lupus anticoagulant, anticardiolipin antibodies, and anti–β 2 -glycoprotein I antibodies—in the antiphospholipid antibody syndrome (APLAS) have been associated with a variety of adverse pregnancy outcomes, including fetal loss. The mechanism of these adverse outcomes remains unclear but likely includes inflammation, thrombosis, and placental infarction. However, the link between fetal death and these antibodies or the presence of APLAS remains under investigation, with insufficient evidence to conclude that an increased risk exists for fetal death.
The cause of fetal death in women with gestational cholestasis remains unknown, and timing and disease characteristics associated with impending fetal death remain unpredictable. Fetal deaths in these pregnancies are not preceded by signs of placental insufficiency such as growth restriction or abnormal placental pathology, and normal fetal heart rate tracings proximal to fetal death (i.e., within 24 hours) have often been reported. It has not been consistently established whether maternal liver enzymes or pharmacologic therapy modify or predict the risk of fetal death, whereas different maternal serum bile acid thresholds ranging from greater than 40 to 100 µmol/L or higher have been associated with adverse outcomes.
With chronic maternal renal disease, perinatal outcome is largely associated with the degree of renal dysfunction and the presence of coexisting hypertension or diabetes. Although data are limited by lack of prospective studies with appropriate control groups, the greatest risk for fetal death appears to be in mothers with severe renal impairment (i.e., serum creatinine levels >2.4 to 2.8 mg/dL). As with maternal renal disease, the prognosis for fetal outcome in women with systemic lupus erythematosus (SLE) is dependent on disease state and comorbid conditions, including hypertension, circulating autoantibodies, and renal involvement. Prognosis for fetal survival in pregnancies complicated by both maternal renal disease and maternal SLE has improved over time with advances in therapies that promote disease quiescence for both of these conditions.
Become a Clinical Tree membership for Full access and enjoy Unlimited articles
If you are a member. Log in here